Amgen (AMGN) reported Q1 FY2023 earnings of $3.98 per share (versus $4.25 per share in Q1 FY2022), beating analysts’ consensus estimate of $3.85 per share.
The company’s quarterly revenues amounted to $6.105 bln (-2.1% y/y), missing analysts’ consensus estimate of $6.177 bln.
The company also issued guidance for FY2023, seeing EPS of $17.60-18.70 versus analysts’ consensus estimate of $17.89 and revenues of $26.2-27.3 bln versus analysts’ consensus estimate of $28.74 bln.
AMGN fell to $239.90 (-0.18%) in pre-market trading.
